Clinical trial

Therapy Optimization in Multiple Sclerosis (MS)

NCT00819000

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2008-12-01

PhaseN/A

Study timeline

Study start (unknown)2008-12-01Date precision: month

Registry last updated2013-01-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Multiple Sclerosisunresolved

Interventions

Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1bDRUG

Sponsors & collaborators

Teva Neuroscience, Inc.lead sponsor

Mapped research locations

ColumbusOhio, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00819000 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.